Nanjing Pharmaceutical (600713.SH): The application for issuing convertible bonds has obtained the approval of the China Securities Regulatory Commission for registration.

Gelonghui, December 4th丨Nanjing Pharmaceutical (600713.SH) announced that the company recently received a reply from the China Securities Regulatory Commission (hereinafter referred to as "China's CSRC") regarding the approval of Nanjing Pharmaceutical Co., Ltd. to issue convertible corporate bonds to unspecified objects (CSRC License [2024] No. 1736). The main content of the approval is as follows: 1. The application for the company's registration to issue convertible corporate bonds to unspecified objects is approved. 2. This issuance by the company must be carried out strictly in accordance with the declaration documents submitted to the Shanghai Stock Exchange and the issuance plan. 3. This approval is effective from the date of consent to register.

Gelonghui FinanceDec 4 16:08

Express News | Nanjing Pharmaceutical: Approval granted for the issuance of ultra-short-term financing bonds.

BreakingsOct 31 15:46

Nanjing Pharmaceutical: Full text of Nanjing Pharmaceutical\'s 2024 third quarter report

SZSIOct 31 00:00 · Announcements

Full text of Nanjing Pharmaceutical\'s 2024 third quarter report

SZSIOct 31 00:00 · Announcements

Express News | Nanjing Pharmaceutical: The net income attributable to the mother in the first three quarters was 0.442 billion yuan, a year-on-year increase of 0.36%.

BreakingsOct 30 15:40

Nanjing Pharmaceutical (600713.SH): The net income for the first three quarters was 0.442 billion yuan, a year-on-year increase of 0.36%.

Gelonghui October 30th | Nanjing Pharmaceutical (600713.SH) announced the third quarter report of 2024, with the company's revenue in the first three quarters of 40.938 billion yuan, a year-on-year increase of 0.97%; net income attributable to shareholders of the listed company was 0.442 billion yuan, a year-on-year increase of 0.36%; basic earnings per share was 0.34 yuan.

Gelonghui FinanceOct 30 15:40